Lilly reports third-quarter 2025 financial results, highlights R&D pipeline momentum and raises 2025 guidance – investor.lilly.com

  1. Lilly reports third-quarter 2025 financial results, highlights R&D pipeline momentum and raises 2025 guidance  investor.lilly.com
  2. Eli Lilly blows past estimates, hikes guidance as Zepbound and Mounjaro sales soar  CNBC
  3. Eli Lilly’s weight loss and diabetes drug tops Keytruda as world’s best-selling medicine  statnews.com
  4. Eli Lilly Smashes Views On Back Of Mounjaro, Zepbound  Investor’s Business Daily
  5. Obesity, diabetes treatments fuel Eli Lilly growth and spark bidding war  Yahoo Finance

Source link

Leave a Reply

Your email address will not be published. Required fields are marked *